-
Medical journals
- Career
Athero Review - Issue 3/2022
Editorial
127
Guidelines
130Statement CSAT on Consensus EAS 2021: Triglyceride-rich lipoproteins and their remnants – metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesMichal Vrablík, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Jan Piťha, Hana Rosolová, Vladimír Soška, Tomáš Štulc, Zuzana Urbanová Za Výbor Čsat, Jana Mašková
Reviews
140Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozinJan Vachek, Kateřina Oulehle, Hana Ciferská, Oskar Zakiyanov, Vladimír Tesař
147Bempedoic acid – a new drug to lower LDL-cholesterol levelVladimír Soška, Ondřej Kyselák
152The importance of diet therapy and the correct regimen in familial hypercholesterolemiaVěra Boháčová, Tamara Starnovská
Clinical Studies
156PACMAN-AMI trial: review of endpointsRoman Margóczy
159What have imaging studies with evolocumab yielded?Tomáš Kovárník, Karel Kopřiva, Jan Pudil, Zhi Chen, Milan Šonka
Personal News
From International Literature
Announcements
169XXXVI. konference o hyperlipoproteinemiích – Šobrův den 2022Kristýna Čillíková
Athero Review
2022 Issue 3
Most read in this issue- Bempedoic acid – a new drug to lower LDL-cholesterol level
- Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin
- Statement CSAT on Consensus EAS 2021: Triglyceride-rich lipoproteins and their remnants – metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies
- Profesor Zdeněk Zadák pětaosmdesátiletý!
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career